Fortrea Holdings Inc. (NASDAQ:FTRE) Q1 2024 Earnings Conference Call May 13, 2024 8:00 AM ET Company Participants Tom Pike - Chairman, Chief Executive Officer Jill McConnell - Chief Financial Officer Hima Inguva - Head of Investor Relations, Corporate Development Conference Call Participants David Windley - Jefferies Elizabeth Anderson - Evercore Patrick Donnelly - Citi Eric Coldwell - Baird Max Smock - William Blair Michael Ryskin - Bank of America Rishi Parekh - JP Morgan Operator Ladies and gentlemen, t ...

Q1 2024 Earnings Presentation Learn more at fortrea.com. ©2024 Fortrea Inc. All rights reserved. Fortrea Q1'2024 Earnings presentation 05.13.2024 FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES In light of these risks, uncertainties and assumptions, the forward-looking statements contained in this presentation might not prove to be accurate and you should not place undue reliance upon them. All forwardlooking statements attributable to us or persons acting on our behalf are expressly qualified in t ...

Exhibit 99.1 Fortrea Reports First Quarter 2024 Results For the three months ended March 31, 2024, from continuing operations: DURHAM, N.C., May 13, 2024— Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2024. "We are making solid progress toward our goal of being the best choice among clinical research organizations for customers large and small, creating a positive and distinctive experienc ...

For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings (loss) per share of $(0.91) and $(0.04), respectivelyBook-to-bill ratio of 1.11x, resulting in >1.2x book-to-bill for the trailing nine monthsPlanned divestiture of assets relating to the Endpoint Clinical and Patient Access businesses on track DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the ...

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced an updated issuance date for the company's first quarter 2024 financial results. The Company requires additional time to work through accounting and discontinued operations matters primarily as a result of entering into a definitive agreement in March 2024 to divest assets relating to the Company's Enabling Services segment. Fortrea will now release its ...

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an updated issuance date for the company’s first quarter 2024 financial results. The Company requires additional time to work through accounting and discontinued operations matters primarily as a result of entering into a definitive agreement in March 2024 to divest assets relating to the Company’s Enabling Services segment. Fortrea will now release it ...

DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations w ...

DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations ...

拟议剥离 Endpoint Clinical 和 Fortrea 患者通道 (Patient Access) 业务，进一步简化 Fortrea 的战略重心，成为纯粹的合同研究组织 创建独立的、一流的随机化 (Randomization) 和试验供应管理 (Trial Supply Management) 以及 Patient Access 解决方案，以实现差异化和增长 北卡罗来纳州，达勒姆市, March 13, 2024 (GLOBE NEWSWIRE) -- Fortrea全球领先的合同研究组织 (CRO) Fortrea (Nasdaq: FTRE)（以下简称“公司”）今天宣布其已签署一项最终协议，剥离与其支持服务 (Enabling Services) 部门相关的资产，即 Endpoint Clinical (“Endpoint”) 和 Fortrea Patient Access 业务，出售给 Arsenal Capital Partners (“Arsenal”)，这是一家专注于打造市场领先、技术丰富的医疗公司的领先私募股权公司。 通过剥离这些业务，Fortrea 旨在推进 Endpoint 和 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-04321 __________________________________ Fortrea Holdings Inc. (Exac ...